---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-364991"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2021-12-22T23:59:59+00:00"
generated_at: "2026-06-27T23:00:22.160877+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zai Lab promotes Harald Reinhart to President and Head of Global Development

## Summary
- Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
- Reinhart received a special equity grant of 30,000 restricted share units, with 50% vesting immediately and 50% on Dec 31, 2022
- Base salary and target bonus for 2022 and 2021 bonus increased to be commensurate with other executive officers
- Reinhart has been with Zai Lab since inception, first as advisor and since 2017 as CMO
- Prior to Zai Lab, he served at Shionogi U.S., Novartis, and Bayer Corp with broad clinical development experience

## SEC filing metadata
- accession: 0001193125-21-364991
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2021-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/0001193125-21-364991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/d278574d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-364991
- JSON: https://secwatch.observer/filing/0001193125-21-364991.json
- Plain text: https://secwatch.observer/filing/0001193125-21-364991.txt

## Key facts
- Executive change
  Harald Reinhart changed role as President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.
  - Action: promoted
  - Role: President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
  source text: On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/0001193125-21-364991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.